Many have written and spoken about the goal of eliminating the effect of developing and delivering medical care in “silos.”
The Tomosynthesis Mammographic Imaging Screening Trial, a massive randomized trial of early detection, is asking an important question:
The number of cases of HPV+ cervical precancers has dropped by 21 percent from 2008 to 2014, according to a survey by the Centers for Disease Control and Prevention.
A University of California, Irvine patient with glioblastoma recently received an experimental cancer vaccine from the U.S. subsidiary of Brussels-based Epitopoietic Research Corp. (ERC-USA). While most cases of patients receiving experimental medical treatment are not particularly newsworthy, this one was.
Last week, the American Cancer Society released its annual Facts and Figures report, showing that we continue to make exceptional progress against cancer, most notably with a 27 percent decline in the death rate across all cancer types over the last 25 years.
In my twenty-two years of practicing medicine, I have observed the evolution of genomic testing and its increasing utility in oncology.
Study shows DNA biomarker can be used to predict outcomes for high risk low grade gliomas
In the spring of 2001, I visited a longtime friend and collaborator, Alexandre Barbault, to share with him my vision of using low levels radiofrequency electromagnetic fields for the treatment of cancer.
Anne-Marie Langevin, of the South Texas Pediatric Minority/Underserved NCI Community Oncology Research Program site in San Antonio, won the 2018 Harry Hynes Award, which is given annually to the PI who reflects the outstanding contribution to clinical trials and community research.
Historically, oncology drug development has evolved on what may seem to be a different planet, at least relative to mainstream clinical pharmacology.
